Stryker Corp. won FDA approval for expanded indication of its Trevo Retriever device for frontline treatment of patients with acute ischemic stroke, widening the time window for the clot removal device from six to 24 hours. The FDA nod followed a change in stroke guidelines issued in late January by the American Heart Association (AHA) and American Stroke Association (ASA) to allow for the longer recommended treatment period thereby increasing the of patients who would undergo clot removal, or thrombectomy. Read More
